# Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

> **NCT02980341** · PHASE1,PHASE2 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 182 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Patritumab Deruxtecan

## Key facts

- **NCT ID:** NCT02980341
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-28
- **Primary completion:** 2021-08-16
- **Final completion:** 2023-09-07
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980341, "Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02980341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*